이상반응 보고
| VAERS ID | 2247514 |
|---|---|
| 성별 | 여성 |
| 나이 | 37세 |
| 주 코드 | FR |
| 제약회사 | MODERNA |
| 로트 번호 | |
| 예방접종 횟수 | 3 |
| 접종일 | 2022-03-03 |
| 발병일 | 2022-03-03 |
| 상태 |
증상
- 가슴 통증(Chest pain)
- 콧물(Rhinorrhoea)
이환 중 질병
지병
Comments: The patient had no history of adverse drug reactions and diseases.
기타 의료
이전 예방접종
알레르기
임상 검사
증상 상세
Runny nose and chest pain; Runny nose and chest pain; This regulatory authority case was reported by an other health care professional and describes the occurrence of RHINORRHOEA (Runny nose and chest pain) and CHEST PAIN (Runny nose and chest pain) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.
The patient had no history of adverse drug reactions and diseases.
On 03-Mar-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.
On 03-Mar-2022, the patient experienced RHINORRHOEA (Runny nose and chest pain) (seriousness criterion medically significant) and CHEST PAIN (Runny nose and chest pain) (seriousness criterion medically significant).
At the time of the report, RHINORRHOEA (Runny nose and chest pain) and CHEST PAIN (Runny nose and chest pain) was resolving.
For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
No concomitant medications were provided by the reporter.
On 11-Mar-2022, the patient came to the special clinic of the hospital for COVID-19 adverse reactions, and the chief complaint was that Moderna (third dose) was received on 03-Mar-2022.
Post that patient experienced nasal dripping, hot sensation and chest tightness.
On 16-Mar-2022, as runny nose and chest pain could not be ruled out from relevance to the adverse reaction of COVID-19 vaccine, the doctor reported the adverse reaction of the COVID-19 vaccine.
After diagnosis and treatment, the patient condition was stable and the continuous follow-up in the out-patient department was allowed.
Out-patient medications included oral Xyzal 1tab QDHS for a total of 7 days.
Physiological measurement information included BT: 37.
6 degree C, CRP Quantitative: 0.
15 mg/L, GOT (AST): 20 IU/L, GPT (ALT): 15 IU/L, Urea N: 11.
6 mg/dL, creatinine: 0.
66 mg/dl, CK-MB(S): 1.
5 ng/ml, Tropo-I: less than 0.
0023 ng/ml.
Company Comment: This regulatory case concerns a 37-year-old, female patient with no reported medical history, who experienced the unexpected, serious (medically significant) events of Rhinorrhoea and Chest pain.
The events occurred on the same day after receiving the third dose of mRNA-1273, along with reported symptoms of post-nasal drip and hot sensation.
The patient had low grade fever (37.
6 degrees Celsius) on presentation while laboratory investigations (inflammatory markers, liver function test, urea and creatinine) were all within normal limits.
The patient was prescribed with oral antihistamine (Xyzal) and was advised out-patient follow-up thereafter.
The benefit-risk relationship of mRNA-1273 is not affected by this report.
Events' seriousness was assessed as per Regulatory Authority's report.
; Sender's Comments: This regulatory case concerns a 37-year-old, female patient with no reported medical history, who experienced the unexpected, serious (medically significant) events of Rhinorrhoea and Chest pain.
The events occurred on the same day after receiving the third dose of mRNA-1273, along with reported symptoms of post-nasal drip and hot sensation.
The patient had low grade fever (37.
6 degrees Celsius) on presentation while laboratory investigations (inflammatory markers, liver function test, urea and creatinine) were all within normal limits.
The patient was prescribed with oral antihistamine (Xyzal) and was advised out-patient follow-up thereafter.
The benefit-risk relationship of mRNA-1273 is not affected by this report.
Events' seriousness was assessed as per Regulatory Authority's report.